Effective November 6, 2022, Alex Wylie resigned as Interim Chairman, Director of Instadose Pharma Corp. and as Interim Chairman, Director of its wholly owned Canadian subsidiary (“Instadose Canada”). Mr. Wylie will not hold any officer or director positions at the company or Instadose Canada following his resignation.

Antonio Franchino will succeed Mr. Wylie as Chairman of the company. The company's Board of Directors initiated a process to find a permanent Chairman and Chief Executive Officer of the commencing in January 2022. The Board of Directors believes that Mr. Franchino is a highly qualified leader to navigate Instadose through its next stage of growth as he has significant past experience in a Chairman role and through his extensive legal training.

Mr. Franchino is based in Luxembourg which is strategic for Instadose as it transitions the majority of its operations to Europe.